 Connection
Myron Levin to Vaccination
This is a "connection" page, showing publications Myron Levin has written about Vaccination.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.043 |
|
|
|
-
Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018 10 01; 128(10):4429-4440.
Score: 0.348
-
Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine. 2018 01 02; 36(1):179-185.
Score: 0.326
-
Johnson RW, Levin MJ. Herpes Zoster and Its Prevention by Vaccination. Interdiscip Top Gerontol Geriatr. 2020; 43:131-145.
Score: 0.098
-
Levin MJ, Weinberg A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clin Infect Dis. 2020 03 17; 70(7):1509-1515.
Score: 0.098
-
Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother. 2019; 15(4):772-777.
Score: 0.090
-
Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Caldas Y, Salazar AT, Canniff J, McCarson BJ, Martin J, Pang L, Levin MJ. Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. J Infect Dis. 2019 01 07; 219(2):335-338.
Score: 0.090
-
Weinberg A, Canniff J, Rouphael N, Mehta A, Mulligan M, Whitaker JA, Levin MJ. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. J Immunol. 2017 07 15; 199(2):604-612.
Score: 0.081
-
Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 08; 16(8):915-22.
Score: 0.074
-
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb; 58(3):309-18.
Score: 0.064
-
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb; 58(3):e44-100.
Score: 0.063
-
Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine. 2013 Oct 01; 31(42):4782-90.
Score: 0.062
-
Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 01; 208(9):1386-90.
Score: 0.062
-
Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013 May; 9(5):1177-84.
Score: 0.059
-
Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Sch?del FP, Annunziato PW, Schlienger K, Silber JL. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults =60 years of age. Vaccine. 2012 Jan 20; 30(5):904-10.
Score: 0.055
-
Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010 May; 48 Suppl 1:S14-9.
Score: 0.049
-
High KP, D'Aquila RT, Fuldner RA, Gerding DN, Halter JB, Haynes L, Hazzard WR, Jackson LA, Janoff E, Levin MJ, Nayfield SG, Nichol KL, Prabhudas M, Talbot HK, Clayton CP, Henderson R, Scott CM, Tarver ED, Woolard NF, Schmader KE. Workshop on immunizations in older adults: identifying future research agendas. J Am Geriatr Soc. 2010 Apr; 58(4):765-76.
Score: 0.049
-
Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S200-6.
Score: 0.042
-
Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM, Pelton SI, Borkowsky W, Edwards KM, Peters J. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics. 2007 Nov; 120(5):e1190-202.
Score: 0.041
-
Laing KJ, Ford ES, Johnson MJ, Levin MJ, Koelle DM, Weinberg A. Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest. 2023 12 01; 133(23).
Score: 0.032
-
Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis. 2003 Oct 01; 188(7):954-9.
Score: 0.031
-
Curran D, Kim JH, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, Cunningham AL, McNeil SA, Schuind AE, Andrew MK. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. J Am Geriatr Soc. 2021 03; 69(3):744-752.
Score: 0.026
-
Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Herv? C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019; 15(12):2865-2872.
Score: 0.023
-
Zaia JA, Levin MJ. Varicella vaccine. Pediatrics. 1979 Feb; 63(2):348.
Score: 0.023
-
Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018 05 05; 217(11):1750-1760.
Score: 0.021
-
Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018 03 14; 36(12):1537-1541.
Score: 0.021
-
Levin MJ. Can herpes zoster be prevented? Eur J Clin Microbiol Infect Dis. 1996 Jan; 15(1):1-3.
Score: 0.018
-
Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015 Mar 15; 60(6):900-9.
Score: 0.017
-
Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013 Apr; 56(8):1085-93.
Score: 0.015
-
Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA, Bryan J, Levin MJ. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis. 2012 Oct; 206(8):1309-18.
Score: 0.014
-
Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15; 55(10):1320-8.
Score: 0.014
-
Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, Moris P, Giannini SL, Schuind A, Datta SK, Descamps D. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011 Dec; 7(12):1359-73.
Score: 0.014
-
Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses. 2011 Mar; 5(2):67-75.
Score: 0.013
-
Oxman MN, Levin MJ. Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S228-36.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|